NEO-SPACE Trial: Neoadjuvant Pembrolizumab-Gemcitabine-Cisplatin Followed by Concurrent Pembrolizumab-Chemoradiation and Maintenance Pembrolizumab for Stage IVA Nasopharyngeal Cancer
Latest Information Update: 19 Feb 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Carcinoma; Cholangiocarcinoma; Lung cancer; Nasopharyngeal cancer
- Focus Therapeutic Use
- Acronyms NEO-SPACE Trial
Most Recent Events
- 12 Feb 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
- 12 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
- 05 Feb 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.